Breaking News, Collaborations & Alliances

Grand Opening of Kodiak Sciences’ Bioconjugation Facility

To support potential commercial manufacture of KSI-301, an antibody biopolymer conjugate for retinal diseases.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Kodiak Sciences, a biopharmaceutical company researching, developing and commercializing therapeutics to treat high prevalence retinal diseases, and Lonza, opened a new, custom-built, bioconjugation facility within Lonza’s Ibex Dedicate manufacturing complex in Visp, Switzerland. The facility will play a key role in the scaled manufacturing of Kodiak’s lead therapeutic candidate KSI-301 to support a potential global commercial launch. Once fully operational and if KSI-301 is approved for comm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters